Opportunities to overcome underutilization of enhanced insulin delivery technologies in people with type 2 diabetes: a narrative review

References

• Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010 Dec;85(12 Suppl):S3–S4. doi: 10.4065/mcp.2010.0466
   PubMedGoogle Scholar
• Grunberger G, Sze D, Ermakova A, et al. Treatment intensification with insulin pumps and other technologies in patients with type 2 diabetes: results of a physician survey in the United States. Clin Diabetes. 2020;38(1):47–55. doi: 10.2337/cd19-0008
   PubMedGoogle Scholar
• International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021 [cited 2023 Jan 31 8]. Available from: https://diabetesatlas.org/atlas/tenth-edition/
   Google Scholar
• Basu S, Yudkin JS, Kehlenbrink S, et al. Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(1):25–33.
   PubMed Web of Science ®Google Scholar
• Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications Trial/Epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16. doi: 10.2337/dc13-2112
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel A, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi: 10.1056/NEJMoa0806470
   PubMed Web of Science ®Google Scholar
• Fang M, Wang D, Coresh J, et al. Trends in diabetes treatment and control in U.S. Adults, 1999–2018. N Eng J Med 2021; 384(23):2219–2228. doi: 10.1056/NEJMsa203227
   PubMed Web of Science ®Google Scholar
• Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019 May 3;10:2042018819844694. doi: 10.1177/2042018819844694
   Web of Science ®Google Scholar
• Khunti K, Nikolajsen A, Thorsted BL, et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diab Obes Metab. 2016;18(4):401–409. doi: 10.1111/dom.12626
   PubMed Web of Science ®Google Scholar
• Brixner D, Ermakova A, Xiong Y, et al. Clinical outcomes of patients with type 2 diabetes treated with multiple daily injection (MDI) of insulin–a retrospective cohort analysis. Clin Ther. 2019;41(2):303–313.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Factors associated with injection omission/non-adherence in the global attitudes of patients and physicians in insulin therapy study. Diab Obes Metab. 2012;14(12):1081. doi: 10.1111/j.1463-1326.2012.01636.x
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543–2545. doi: 10.2337/diacare.28.10.2543
   PubMed Web of Science ®Google Scholar
• Świątoniowska-Lonc N, Tański W, Polański J, et al. Psychosocial determinants of treatment adherence in patients with type 2 diabetes - a review. Diabetes Metab Syndr Obes. 2021 Jun 16;14: 2701–2715. doi: 10.2147/DMSO.S308322
   PubMed Web of Science ®Google Scholar
• Song Y, Song H-J, Han H-R, et al. Unmet needs for social support and effects on diabetes self-care activities in Korean Americans with type 2 diabetes. Diabetes Educ. 2012;38(1):77–85. doi: 10.1177/0145721711432456
   PubMed Web of Science ®Google Scholar
• Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604. doi: 10.1038/s41574-018-0048-7
   PubMed Web of Science ®Google Scholar
• Orenius T, LicPsych, Säilä H, et al. Fear of injections and needle phobia among children and adolescents: an overview of psychological, behavioral, and contextual factors. SAGE Open Nursing. 2018 Mar 14;4:2377960818759442. doi: 10.1177/2377960818759442
   Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012 May;29(5):682–689.
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care. 2023 Jan;46(Supplement 1):S140–S157. doi: 10.2337/dc23-S009
   PubMedGoogle Scholar
• Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489–2496. doi: 10.2337/dc12-2454
   PubMed Web of Science ®Google Scholar
• Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403–412. doi: 10.2147/DMSO.S141235
   PubMed Web of Science ®Google Scholar
• Hemmer A, Maiter D, Buysschaert M, et al. Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: a retrospective real-life study in 131 patients. Diabetes Metab Syndr. 2019 Jan;13(1):332–336.
   PubMed Web of Science ®Google Scholar
• Chlup R, Runzis S, Castaneda J, et al. Complex assessment of metabolic effectiveness of insulin pump therapy in patients with type 2 diabetes beyond HbA1c reduction. Diabetes Technol Ther. 2018;20(2):153–159. doi: 10.1089/dia.2017.0283
   PubMed Web of Science ®Google Scholar
• Ghazanfar H, Rizvi SW, Khurram A, et al. Impact of insulin pump on quality of life of diabetic patients. Indian J Endocrinol Metab. 2016 Jul;20(4):506–511. doi: 10.4103/2230-8210.183472
   PubMedGoogle Scholar
• Honish A, Westerfield W, Ashby A, et al. Health-related quality of life and treatment compliance with diabetes care. Dis Manage. 2006;9(4):195–200. doi: 10.1089/dis.2006.9.195
   PubMedGoogle Scholar
• McAdams BH, Rizvi AA. An overview of insulin pumps and glucose sensors for the generalist. J Clin Med. 2016;5(1):5. doi: 10.3390/jcm5010005
   PubMed Web of Science ®Google Scholar
• Tanenbaum ML, Hanes SJ, Miller KM, et al. Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets. Diabetes Care. 2017 Feb;40(2):181–187.
   PubMed Web of Science ®Google Scholar
• Freckmann G, Buck S, Waldenmaier D, et al. Insulin pump therapy for patients with type 2 diabetes mellitus: evidence, current barriers, and new technologies. J Diabetes Sci Technol. 2021 Jul;15(4):901–915. doi: 10.1177/1932296820928100
   PubMedGoogle Scholar
• Tanenbaum ML, Adams RN, Hanes SJ, et al. Optimal use of diabetes devices: clinician perspectives on barriers and adherence to device use. J Diabetes Sci Technol. 2017;11(3):484–492. doi: 10.1177/1932296816688010
   PubMedGoogle Scholar
• Fantasia KL, Wirunsawanya K, Lee C, et al. Racial disparities in diabetes technology use and outcomes in type 1 diabetes in a safety-net hospital. J Diabetes Sci Technol. 2021;15(5):1010–1017. doi: 10.1177/1932296821995810
   PubMedGoogle Scholar
• Agarwal S, Schechter C, Gonzalez, et al. Racial–ethnic disparities in diabetes technology use among young adults with type 1 diabetes. Diabetes Technol Ther. 2021 Apr;23(4):306–313. doi: 10.1089/dia.2020.0338
   PubMed Web of Science ®Google Scholar
• Lai CS, Terri H, Lipman TH, et al. Racial and ethnic disparities in rates of continuous glucose monitor initiation and continued use in children with type 1 diabetes. Diabetes Care 2021;44(1):255–257. doi: 10.2337/dc20-1663
   PubMed Web of Science ®Google Scholar
• Willi SM, Miller KM, DiMeglio LA, et al. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. Pediatrics. 2015;135(3):424–434.
   PubMed Web of Science ®Google Scholar
• Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145–154.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ji L, Ran X, et al. Gender disparities in lipid goal attainment among type 2 diabetes outpatients with coronary heart disease: results from the CCMR-3B study. Sci Rep. 2017 Oct 4;7(1):12648. doi: 10.1038/s41598-017-13066-z
   PubMedGoogle Scholar
• Beck RW, Bergenstal RM, Laffel LM, et al. Advances in technology for management of type 1 diabetes. Lancet. 2019;394(10205):1265–73. doi: 10.1016/S0140-6736(19)31142-0
   PubMed Web of Science ®Google Scholar
• Statista. Number of active physicians in the U.S. in 2022, by specialty area. [cited 2022 Oct 30]. Available from: https://www.statista.com/statistics/209424/us-number-of-active-physicians-by-specialty-area/
   Google Scholar
• Oser SM, Oser TK. Diabetes Technologies: We Are All in this Together. Clin Diabetes. 2020 Apr;38(2):188–9. doi: 10.2337/cd19-0046 PMID: 32327892.
   PubMedGoogle Scholar
• Vigersky RA, Fish L, Hogan P, et al. The clinical endocrinology workforce: current status and future projections of supply and demand. J Clin Endocrinol Metab. 2014 Sep;99(9):3112–3121.
   PubMed Web of Science ®Google Scholar
• Scott A, O’Cathain A, Goyder E. Socioeconomic disparities in access to intensive insulin regimens for adults with type 1 diabetes: a qualitative study of patient and healthcare professional perspectives. Int J Equity Health. 2019;18:150. doi: 10.1186/s12939-019-1061-8
   PubMed Web of Science ®Google Scholar
• Aleppo G, Parkin CG, Carlson AL, et al. Lost in translation: a disconnect between the science and medicare coverage criteria for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2021;23(10):715–725. doi: 10.1089/dia.2021.0196
   PubMed Web of Science ®Google Scholar
• Center for Health Care Strategies. Expanding Medicaid Access to Continuous Glucose Monitors. 2022 Jan. Available from: https://www.chcs.org/media/Expanding-Medicaid-Access-to-Continuous-Glucose-Monitors_011222.pdf
   Google Scholar
• Gajewska KA, Biesma R, Bennett K, et al. Barriers and facilitators to accessing insulin pump therapy by adults with type 1 diabetes mellitus: a qualitative study. Acta Diabetol. 2021;58(1):93–105. doi: 10.1007/s00592-020-01595-5
   PubMed Web of Science ®Google Scholar
• O’Donovan A, Oser SM, Parascando J, et al. Determining the perception and willingness of primary care providers to prescribe advanced diabetes technologies. J Patient Cent Res Rev. 2021;8(3):272–276.
   PubMed Web of Science ®Google Scholar
• Bergloff A, Stratton E, Briggs Early K. A cross-sectional pilot survey of rural clinic attitudes and proficiency with insulin pumps and continuous glucose monitoring devices. Diabetes Technol Ther. 2019 Nov;21(11):665–670. doi: 10.1089/dia.2019.0161
   PubMed Web of Science ®Google Scholar
• Ginsberg BH. Patch pumps for insulin. J Diabetes Sci Technol. 2019;13(1):27–33. doi: 10.1177/1932296818786513
   PubMedGoogle Scholar
• Ekanayake P, Edelman S. Identifying those patients with type 2 diabetes who might benefit from insulin pump therapy: literature review, clinical opportunities, potential benefits & challenges. Diab Obes Metab. 2023 Mar 22;25(S2):3–20. doi: 10.1111/dom.15059
   PubMedGoogle Scholar
• Parkner T, Møller MK, Chen JW, et al. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes. Diab Obes Metab. 2008;10(7):556–563. doi: 10.1111/j.1463-1326.2007.00748.x
   PubMed Web of Science ®Google Scholar
• Taylor M, Sahota T. New technologies in insulin delivery. Pract Diabetes. 2013;30(1):21–26. doi: 10.1002/pdi.1736
   Google Scholar
• Asian Hospital & Healthcare Management. Novel Sigi™ insulin management system developed for diabetes mellitus treatment. [cited 2023 Dec 26]. Available from: https://www.asianhhm.com/technotrends/novel-sigi-insulin-management-system-developed-for-diabetes-mellitus-treatment
   Google Scholar
• Davies MJ, Gagliardino JJ, Gray LJ, et al. Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30(5):512–24. doi: 10.1111/dme.12128
   PubMed Web of Science ®Google Scholar
• Heinemann L, Waldenmaier D, Kulzer B, et al. Patch pumps: are they all the same? J Diabetes Sci Technol. 2019;13(1):34–40. doi: 10.1177/1932296818795150
   PubMedGoogle Scholar
• Reznik Y, Cohen O Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes. Diabetes Care. 2013;36(suppl 2):s219–s225. doi: 10.2337/dcS13-2027
   PubMed Web of Science ®Google Scholar
• Ziegler R, Waldenmaier D, Kamecke U, et al. Accuracy assessment of bolus and basal rate delivery of different insulin pump systems used in insulin pump therapy of children and adolescents. Pediatr Diabetes. 2020;21(4):649–656.
   PubMed Web of Science ®Google Scholar
• Laubner K, Singler E, Straetener J, et al. Comparative dose accuracy of durable and patch insulin pumps under laboratory conditions. Diabetes Technol Ther. 2019;21(7):371–378. doi: 10.1089/dia.2019.0089
   PubMed Web of Science ®Google Scholar
• Heinemann L, Krisiunas L. Diabetes technology and waste: a complex problem piling up!. J Diabetes Sci Technol. 2019;13(5):815–816. doi: 10.1177/1932296819836395
   PubMedGoogle Scholar
• Herman A, de Montjoye L, Tromme I, et al. Allergic contact dermatitis caused by medical devices for diabetes patients: a review. Contact Dermatitis. 2018;79(6):331–335. doi: 10.1111/cod.13120
   PubMed Web of Science ®Google Scholar
• Lajara R, Fetchick DA, Morris TL, et al. Use of V-Go® insulin delivery device in patients with sub-optimally controlled diabetes mellitus: a retrospective analysis from a large specialized diabetes system. Diabetes Ther. 2015;6:531–545. 4 10.1007/s13300-015-0138-7
   PubMed Web of Science ®Google Scholar
• Lajara R, Davidson JA, Nikkel CC, et al. Clinical and cost-effectiveness of insulin deliver with V-Go® disposable insulin deliver device versus multiple daily injections in patients with type 2 diabetes inadequately controlled on basal insulin. Endocr Pract. 2016;22(6):726–735. doi: 10.4158/EP151182.OR
   PubMed Web of Science ®Google Scholar
• Lajara R, Nikkel C, Abbott S. The clinical and economic impact of the V-Go® disposable insulin delivery device for insulin delivery in patients with poorly controlled diabetes at high risk. Drugs Real World Outcomes. 2016 Jun;3(2):191–199. doi: 10.1007/s40801-016-0075-4
   PubMedGoogle Scholar
• Sutton D, Charissa D, Higdon CD, et al. Clinical benefits over time associated with use of V-Go wearable insulin delivery device in adult patients with diabetes: a retrospective analysis. Adv Ther. 2018;35(5):631–643. doi: 10.1007/s12325-018-0703-3
   PubMed Web of Science ®Google Scholar
• Grunberger G, Rosenfeld CR, Bode BW, et al. Effectiveness of V-Go® for patients with type 2 diabetes in a real-world setting: a prospective observational study. Drugs Real World Outcomes. 2020 Mar;7(1):31–40.
   PubMedGoogle Scholar
• Bohannon N, Bergenstal R, Cuddihy R, et al. Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. Diabetes Technol Ther. 2011;13(10):1031–1037. doi: 10.1089/dia.2011.0047
   PubMed Web of Science ®Google Scholar
• Mader JK, Lilly LC, Aberer F, et al. A feasibility study of a 3-day basal-bolus insulin delivery device in individuals with type 2 diabetes. Diabetes Care. 2014 May;37(5):1476–9. doi: 10.2337/dc13-2238
   PubMed Web of Science ®Google Scholar
• Mader JK, Lilly LC, Aberer F, et al. Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with type 2 diabetes. Diabet Med. 2018 Oct;35(10):1448–1456.
   PubMed Web of Science ®Google Scholar
• Layne JE, Parkin CG, Zisser H. Efficacy of a tubeless patch pump in patients with type 2 diabetes previously treated with multiple daily injections. J Diabetes Sci Technol. 2017;11(1):178–179. doi: 10.1177/1932296816653143
   PubMedGoogle Scholar
• Sutton D, Higdon C, Carmon M, et al. Regular insulin administered with the V-Go disposable insulin delivery device in a clinical diabetes setting: a retrospective analysis of efficacy and cost. Clin Diabetes. 2016 Oct;34(4):201–205. doi: 10.2337/cd16-0021
   PubMedGoogle Scholar
• Hermans N, Lilly LC, Mader JK, et al. Novel simple insulin delivery device reduces barriers to insulin therapy in type 2 diabetes. J Diabetes Sci Technol. 2015 May;9(3):581–587.
   PubMedGoogle Scholar
• Isaacs D, Kruger DF, Shoger D, et al. Patient perceptions of satisfaction and quality of life regarding use of a novel insulin delivery device. Clin Diabetes. 2022;41(2):198–207. doi: 10.2337/cd22-0034
   Google Scholar
• Wahlqvist P, Warner J, Morlock R. A cost-effectiveness of simple insulin infusion devices compared to multiple daily injections in uncontrolled type 2 diabetics in the united states based on a simulation model. JHEOR. 2018;6(1):84–95. doi: 10.36469/9789
   Google Scholar
• Cziraky MJ, Abbott S, Nguyen M, et al. A pragmatic clinical trial to compare the real-world effectiveness of V-Go versus standard delivery of insulin in patients with advanced type 2 diabetes. JHEOR. 2019;6(2):70–83. doi: 10.36469/9731
   Google Scholar
• Carlson AL, Huyett LM, Jantz J, et al. Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system. Diabet Res Clin Pract. 2021 Mar 9;174 [cited 2021 Apr 26]. 108735. Available from: https://pubmed.ncbi.nlm.nih.gov/33711396/
   PubMed Web of Science ®Google Scholar
• Thompson B, Cook CB. Insulin pumping patches: emerging insulin delivery systems. J Diabetes Sci Technol. 2019;13(1):8–10. doi: 10.1177/1932296818814541
   PubMedGoogle Scholar
• Sutton D, Higdon C, Carmon M, et al. Regular insulin administered with the V-Go disposable insulin delivery device in a clinical diabetes setting: a retrospective analysis of efficacy and cost. Clin Diabetes. 2016;34(4):201–205. doi: 10.2337/cd16-0021
   PubMedGoogle Scholar
• Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240–245. doi: 10.2337/dc09-1348
   PubMed Web of Science ®Google Scholar
• Pauley ME, Berget C, Messer LH, et al. Barriers to uptake of insulin technologies and novel solutions. Med Devices (Auckl). 2021;14:339–354. doi: 10.2147/MDER.S312858
   PubMedGoogle Scholar
• Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social determinants of health and diabetes: a scientific review. Diabetes Care. 2021;44(1):258–279. doi: 10.2337/dci20-0053
   Web of Science ®Google Scholar
• Kazemian P, Shebl FM, McCann N, et al. Evaluation of the cascade of diabetes care in the United States, 2005-2016. JAMA Intern Med. 2019;179:1376–1385. doi: 10.1001/jamainternmed.2019.2396
   PubMed Web of Science ®Google Scholar